Cartesian Therapeutics (RNAC) Other Non-Current Liabilities (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Other Non-Current Liabilities of $47000.0 for Q1 2026, down 97.67% year-over-year from $2.0 million in Q1 2025, and down 66.67% quarter-over-quarter from $141000.0 in Q4 2025.
Cartesian Therapeutics (RNAC) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Other Non-Current Liabilities for 11 consecutive years, with $47000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 97.67% year-over-year to $47000.0; the TTM figure through Mar 2026 stood at $47000.0 (down 97.67% YoY), while the FY2025 annual figure was $141000.0, down 96.32% from the prior year.
- Other Non-Current Liabilities slipped to $47000.0 in Q1 2026 per RNAC's latest filing, from $141000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $33.5 million in Q3 2022 and bottomed at $47000.0 in Q1 2026.
- Historically, Other Non-Current Liabilities has averaged $10.0 million across 5 years, with a median of $5.7 million in 2023.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities jumped 236.12% — and 2026, when it sank 97.67%.
- Cartesian Therapeutics' Other Non-Current Liabilities stood at $19.1 million in 2022, then slumped by 70.36% to $5.7 million in 2023, then plunged by 32.39% to $3.8 million in 2024, then tumbled by 96.32% to $141000.0 in 2025, then slumped by 66.67% to $47000.0 in 2026.
- Business Quant data shows RNAC's Other Non-Current Liabilities at $47000.0 in Q1 2026, $141000.0 in Q4 2025, and $848000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 165,000.00 |
| Mar 31, 2026 | 47,000.00 |
| Dec 31, 2025 | 141,000.00 |
| Sep 30, 2025 | 848,000.00 |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Dec 31, 2024 | 3.84 Mn |
| Sep 30, 2024 | 3.59 Mn |
| Jun 30, 2024 | 8.06 Mn |
| Mar 31, 2024 | 4.76 Mn |
| Dec 31, 2023 | 5.67 Mn |
| Sep 30, 2023 | 13.09 Mn |
| Jun 30, 2023 | 16.88 Mn |
| Mar 31, 2023 | 23.22 Mn |
| Dec 31, 2022 | 19.14 Mn |
| Sep 30, 2022 | 33.47 Mn |
| Jun 30, 2022 | 26.93 Mn |
| Mar 31, 2022 | 6.91 Mn |
| Dec 31, 2021 | 25.42 Mn |
| Sep 30, 2021 | 40.04 Mn |